The sample copy of this report is available for access.
The Europe Human Milk Oligosaccharides Market is expected to reach USD 210.6 million by 2031, growing at a CAGR of 11.1% during 2026 - 2033.
The Germany and UK led the Europe Human Milk Oligosaccharides Market by Country with a market share of 21% and 17.1% in 2025.The Spain market is expected to witness a CAGR of 12.5% during throughout the forecast period.
The Europe Human Milk Oligosaccharides (HMO) Market originated from increasing scientific understanding of HMOs as critical bioactive compounds naturally present in human breast milk that support infant immunity, gut microbiota development, and overall health. Early market development was driven by advances in analytical technologies and biotechnology that enabled the identification, characterization, and commercial production of HMOs through microbial fermentation and enzymatic synthesis.
The market is driven by increasing demand for premium infant nutrition products, rising awareness regarding microbiome health, expanding applications of HMOs in functional nutrition, and continuous advancements in fermentation technologies. Manufacturers are investing in research and development to improve production efficiency, expand HMO portfolios, and develop innovative formulations targeting digestive health, immune support, and cognitive development. Additionally, stringent European regulatory standards continue to enhance consumer confidence and support market growth.
Leading companies focus on technological innovation, strategic collaborations, production capacity expansion, and regulatory compliance. Investments in advanced fermentation technologies, analytical capabilities, and sustainable manufacturing processes continue to strengthen competitiveness and accelerate commercialization across Europe.
Based on Application, the Europe Human Milk Oligosaccharides Market is segmented into Infant Formula, Dietary Supplements, Food & Beverages, and Pharmaceuticals. The Infant Formula market dominated the Europe Human Milk Oligosaccharides Market by Application in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 160.4 million by 2033, growing at a CAGR of 10.7 % during the forecast period. The Dietary Supplements market is expected to witness a CAGR of 11.7% during (2026 - 2033).
The Infant Formula segment garnered the highest revenue share in the market owing to increasing demand for advanced infant nutrition products that closely replicate the functional benefits of breast milk. Dietary Supplements also recorded a significant share due to growing consumer interest in gut health, immunity, and microbiome-focused nutrition. Meanwhile, Food & Beverages and Pharmaceuticals continue to gain traction as manufacturers increasingly incorporate HMOs into functional nutrition products and therapeutic applications.
Based on Type, the Europe Human Milk Oligosaccharides Market is segmented into 2’FL, LNnT, 3’FL, 6’SL, 3’SL, LNT, and DFL. The 2’FL market dominated the Europe Human Milk Oligosaccharides Market by Type in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 85.7 million by 2033, growing at a CAGR of 9.9 % during the forecast period. The LNnT market is expected to witness a CAGR of 10.1% during (2026 - 2033).
The 2’FL segment garnered the highest revenue share in the market owing to extensive clinical validation, strong regulatory acceptance, and widespread adoption in infant nutrition products. LNnT also recorded a significant share due to increasing use in premium infant formula formulations. Meanwhile, 3’FL, 6’SL, 3’SL, LNT, and DFL continue to witness growing adoption as manufacturers seek to replicate the complexity and nutritional functionality of human breast milk.
Free Valuable Insights: The Worldwide Human Milk Oligosaccharides Market is projected to reach USD 891.2 Million billion by 2033, at a CAGR of 11.3%
Based on Country, the Europe Human Milk Oligosaccharides Market is segmented into Germany, United Kingdom, France, Russia, Spain, Italy, and Rest of Europe. The Germany market dominated the Europe Human Milk Oligosaccharides Market by Country in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 40.8 million by 2031, growing at a CAGR of 9.5 % during the forecast period. The UK market is expected to witness a CAGR of 10% during (2026 - 2033).
Germany acquired a major share of the market owing to its strong biotechnology industry, advanced infant nutrition sector, and significant investments in HMO research and production technologies. The United Kingdom and France also recorded notable market shares supported by increasing adoption of premium infant nutrition products, strong regulatory frameworks, and expanding investments in biotechnology innovation.
By Application
By Type
By Country
Set to reach $210.6 Million by 2031, growing at 11.1% CAGR during 2026-2033.
Germany leads with a market share of 21% in 2025, reaching $40.8 million by 2031.
Infant Formula segment will reach $160.4 million by 2033, growing at 10.7% CAGR during the forecast period.
Dietary Supplements segment is expected to grow at a CAGR of 11.7% during 2026-2033.
The UK market is expected to witness a CAGR of 10% during 2026-2033.
2’FL segment will reach $85.7 million by 2033, growing at a CAGR of 9.9% during the forecast period.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 